<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899626</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000584214</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VU-VICC-GI-0283</secondary_id>
    <secondary_id>VU-VICC-010680</secondary_id>
    <nct_id>NCT00899626</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Patients and Healthy Participants</brief_title>
  <official_title>Novel Colon Cancer Markers in Gastrointestinal Tissue and Biofluids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from&#xD;
      patients with cancer and from healthy participants may help doctors identify and learn more&#xD;
      about biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research study is looking at gastrointestinal biomarkers in tissue and&#xD;
      biological fluid samples from patients and healthy participants undergoing colonoscopy,&#xD;
      endoscopy, or surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify new potential biomarkers of increased gastrointestinal cancer risk using tissue&#xD;
           and biofluid samples from patients and healthy volunteers undergoing colonoscopy,&#xD;
           endoscopy, or surgery.&#xD;
&#xD;
        -  Develop new screening strategies based on substances found in tissue and biofluid&#xD;
           samples.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients and healthy volunteers undergo colonoscopy, endoscopy, or surgery. Patients and&#xD;
      healthy volunteers also undergo tissue (e.g., tumor or normal mucosa) and biofluid (e.g.,&#xD;
      blood, urine, cyst fluids or tumor cells, bile and pancreatic juices, and/or stool) sample&#xD;
      collection. Samples are analyzed for tumor markers by proteomic methods and protein analysis.&#xD;
      If candidate biomarkers are identified, samples are stored for future studies involving these&#xD;
      biomarkers. Information, including demographics, personal and family history of cancer, and&#xD;
      prior and current colonoscopy, endoscopy, or surgery results, is collected from the medical&#xD;
      record and stored in the project database.&#xD;
&#xD;
      Patients and healthy volunteers are followed once a year for up to 5 years to determine if&#xD;
      biomarkers have a prognostic significance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of new potential biomarkers of increased gastrointestinal cancer risk using tissue and biofluid samples from patients and healthy volunteers undergoing colonoscopy, endoscopy, or surgery</measure>
    <time_frame>Indefinately</time_frame>
    <description>Genomic and proteomic biomarkers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of new screening strategies based on substances found in tissue and biofluid samples</measure>
    <time_frame>Indefinately</time_frame>
    <description>Genomic and proteomic biomarker discovery</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biologic sample preservation procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic colonoscopy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic endoscopic procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic endoscopic surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>screening colonoscopy</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Tissue, Body Fluids&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with GI malignancy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis of gastrointestinal (GI) cancer, polyps, or inflammatory bowel disease&#xD;
&#xD;
               -  History of previously treated GI cancer, polyps, or inflammatory bowel disease&#xD;
&#xD;
               -  Healthy volunteer&#xD;
&#xD;
          -  Undergoing colonoscopy or endoscopy for diagnostic or screening purposes at the&#xD;
             Vanderbilt University Medical Center or at the Veterans Affairs Medical Center&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Hemoglobin â‰¥ 8.0 g/dL&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile participants must use effective contraception&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
          -  Not mentally or medically impaired&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert D Beauchamp, MD</last_name>
    <phone>6155169958</phone>
    <phone_ext>6155169958</phone_ext>
    <email>daniel.beauchamp@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keeli B Lewis</last_name>
    <phone>6153438401</phone>
    <email>keeli.b.lewis@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert D Beauchamp, MD</last_name>
      <phone>615-322-2391</phone>
      <email>daniel.beauchamp@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert D Beauchamp, MD</last_name>
      <phone>615-322-2391</phone>
      <email>daniel.beauchamp@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Veterans Affairs Medical Center - Nas</last_name>
      <phone>615-327-4751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Vanderbilt-Ingram Cancer Center</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010 Mar;138(3):958-68. doi: 10.1053/j.gastro.2009.11.005. Epub 2009 Nov 13.</citation>
    <PMID>19914252</PMID>
  </reference>
  <reference>
    <citation>Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut. 2012 Sep;61(9):1291-8. doi: 10.1136/gutjnl-2011-300812. Epub 2011 Oct 13.</citation>
    <PMID>21997556</PMID>
  </reference>
  <reference>
    <citation>Tripathi MK, Deane NG, Zhu J, An H, Mima S, Wang X, Padmanabhan S, Shi Z, Prodduturi N, Ciombor KK, Chen X, Washington MK, Zhang B, Beauchamp RD. Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer. Cancer Res. 2014 Dec 1;74(23):6947-57. doi: 10.1158/0008-5472.CAN-14-1592. Epub 2014 Oct 15.</citation>
    <PMID>25320007</PMID>
  </reference>
  <reference>
    <citation>Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Sci Rep. 2016 Sep 14;6:33273. doi: 10.1038/srep33273.</citation>
    <PMID>27623752</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Beauchamp</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>adenomatous polyp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

